Germline gene therapy pioneer, teenage son make case for safe treatment

OHSU’s Shoukhrat Mitalipov, son publish perspective in Nature Medicine

By Erik Robinson June 03, 2019 Portland, Oregon

Downloads

Shoukhrat Mitalipov, Ph.D., (left) director of the OHSU Center for Embryonic Cell and Gene Therapy, co-authored an editorial with his 17-year-old son, Paul Mitalipov, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)

The case for gene editing

Paul Mitalipov, 17, recently co-authored a paper with his father Shoukhrat Mitalipov, Ph.D., (right) director of the OHSU Center for Embryonic Cell and Gene Therapy, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)

The case for gene editing

Shoukhrat Mitalipov, Ph.D., (right) director of the OHSU Center for Embryonic Cell and Gene Therapy, co-authored an editorial with his 17-year-old son, Paul Mitalipov, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)

The case for gene editing

Danielle Mitalipov

Danielle Nargiz Mitalipov, 20, co-authored two papers in 2014 and 2015 while volunteering in her father Shoukhrat Mitalipov's lab. (Photo courtesy of Danielle Mitalipov)

Paul Mitalipov

Paul Mitalipov, 17, recently co-authored a paper with his father Shoukhrat Mitalipov, Ph.D., director of the OHSU Center for Embryonic Cell and Gene Therapy, making the case for using gene-editing tools to prevent inherited disease. (OHSU/Kristyna Wentz-Graff)